ACADIA projects $1.7 billion in 2028 sales, launches new DAYBUE formulation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
January 13, 2026 9:00 AM EST- 2028 projected combined net sales of approximately $1.7 billion including ~$1 billion for NUPLAZID® and ~$700 million for DAYBUE®
- Top-line results from the Phase 2 RADIANT study of remlifanserin (formerly ACP-204) in Alzheimers disease psychosis anticipated between August and October 2026
- U.S. launch of DAYBUE® STIX on a limited basis begins Q1 2026, with full launch planned Q2 2026
SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's... More
